Solid Biosciences (SLDB) Total Current Liabilities (2017 - 2026)

Solid Biosciences has disclosed Total Current Liabilities across 10 years of filings, most recently posting $30.3 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $30.3 million, up 5.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.3 million (up 5.23% YoY), and the FY2025 annual result was $33.5 million, up 10.63% from the prior year.
• Total Current Liabilities came in at $30.3 million for Q1 2026 at Solid Biosciences, down from $33.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $36.3 million in Q3 2025 to a low of $14.3 million in Q1 2024.
• The 5-year median for Total Current Liabilities is $21.7 million (2022), against an average of $23.0 million.
• Across the five-year window, Total Current Liabilities slumped 35.5% in 2023 and surged 108.42% in 2024, its largest moves.
• Solid Biosciences' Total Current Liabilities stood at $22.5 million in 2022, then plunged by 35.5% to $14.5 million in 2023, then soared by 108.42% to $30.3 million in 2024, then advanced by 10.63% to $33.5 million in 2025, then retreated by 9.53% to $30.3 million in 2026.
• The last three Total Current Liabilities figures came in at $30.3 million (Q1 2026), $33.5 million (Q4 2025), and $36.3 million (Q3 2025), per Business Quant data.